News
Sanofi buys Vigil Neuroscience for $470m
Digest more
Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...
Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...
Sanofi is expanding its neuroscience drug pipeline through the $470 million acquisition(Opens in a new window) of Vigil Neuroscience, a clinical-stage biotech with a ...
Vigil’s team are a welcome addition, and we look forward to working with them and the patient community.” Terms of the Transaction Under the terms of the merger agreement, Sanofi and Vigil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback